Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA

US9238824B2 · kind B2 · utility

Assignees

• INSTITUT PASTEUR · FR
• Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR

Inventors

• Pierre Charneau · Paris, FR
• Veronique Zennou · Paris, FR
• Francoise Pflumio · Belleville, FR
• Aude Sirven · Paris, FR
• Anne DUBART KUPPERSCHMITT · Choisy-le-Roi, FR

Key dates

• Filing date: Jul 15, 2013
• Grant date: Jan 19, 2016
• Expiry date: Mar 16, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2830/60
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.